EMA Withdrawn: Riprazo HCT (aliskiren;hydrochlorothiazide) — Novartis Europharm Ltd.

View source ↗

Summary

EMA withdrew Riprazo HCT (aliskiren and hydrochlorothiazide) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Aliskiren/hydrochlorothiazide (aliskiren/hydrochlorothiazide)
• Riprazo HCT

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Novartis Europharm Ltd.. Decision date: 30/08/2012